The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug Interaction in people living with HIV: Case series report

The clinical impact of rifampicin-based anti-TB therapy and tenofovir alafenamide-containing ARV regimen drug Interaction in people living with HIV: Case series report

Background: People living with HIV (PLWH) are prone to developing tuberculosis (TB). Since tenofovir alafenamide (TAF) is the recommended tenofovir (TFV) prodrug and rifampicin is a key component of TB therapy, thus complicating HIV and TB coinfection management. However, there is little data regard...

Full description

Bibliographic Details
Main Authors: Yahya Ali Mohzari, Mohammed AL Musawa, Ahmad Alrashed, Bandar Zaeri, Nader Damfu, Peter Cahusac, Sana Alwafai, Ahmad Alamer, Abdulaziz Almulhim
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Journal of Infection and Public Health
Subjects:
Rifampicin-based anti-TB therapy
TAF-containing ARV regimen
HIV
Tuberculosis
Drug-drug interaction
Viral load suppression
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034123003386

Internet

http://www.sciencedirect.com/science/article/pii/S1876034123003386

Similar Items